Targeting the STAT5A-LCP2-NF-κB Pathway to Overcome PD-1 Resistance in Esophageal Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Esophageal squamous cell carcinoma (ESCA) poses significant treatment challenges, particularly regarding resistance to immune checkpoint inhibitors like programmed death-1 (PD-1) therapy.
• Understanding the molecular mechanisms underlying immune evasion in ESCA is crucial for developing more effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of lymphocyte cytosolic protein 2 (LCP2) in ESCA.
• To elucidate the molecular mechanisms by which LCP2 mediates resistance to PD-1 therapy in ESCA.
• To identify potential therapeutic targets within the LCP2 regulatory axis.

Main Methods:

• Bioinformatic analysis of LCP2 expression in ESCA using public databases and validation in clinical specimens.
• Functional studies utilizing patient-derived organoids and xenograft models to assess LCP2's impact on macrophage polarization, T cell exhaustion, and PD-1 therapy response.
• Mechanistic investigations involving NF-κB inhibition, STAT5A knockdown, and chromatin immunoprecipitation assays to define the STAT5A-LCP2-NF-κB signaling pathway.

Main Results:

• LCP2 is upregulated in ESCA, correlating with advanced stage, metastasis, and poor prognosis.
• Tumor-intrinsic LCP2 promotes M2 macrophage polarization and CD8+ T cell exhaustion via NF-κB activation, regulated transcriptionally by STAT5A.
• LCP2 knockdown or STAT5A inhibition suppressed immunosuppressive cytokines, restored T cell function, inhibited tumor growth, and synergized with PD-1 blockade, increasing CD8+ T cell infiltration.

Conclusions:

• The STAT5A-LCP2-NF-κB axis is a key mediator of immune escape and PD-1 resistance in ESCA by remodeling the immunosuppressive tumor microenvironment.
• Targeting this axis presents a promising novel therapeutic strategy to overcome immunotherapy resistance in esophageal cancer.